SciBrunch Therapeutics announced the completion of an oversubscribed Pre-A round financing of over $35 million.

This round was led by HighLight Capital, a prominent investor in the biopharmaceutical sector, with participation from InnoPinnacle Fund. Existing shareholders including HanKang Capital, BioTrack Capital, LongRiver Investments, and Elikon Venture also increased their investment.

This marks another financing round completed by SciBrunch within one year following its angel round in June 2025, bringing the total capital raised in the two rounds to $65 million.

The proceeds of this financing round will be mainly used for:

• Accelerating the clinical development of its core pipeline candidate SPR1020, a next-generation highly selective PARP1 inhibitor with significant brain penetration potential. The first patient was dosed on January 8, 2026.

• Advancing IND-enabling studies for a new generation of innovative molecular glue RAS inhibitors, exploring their clinical potential in RAS-mutated refractory tumors including colorectal cancer, pancreatic cancer, and non-small cell lung cancer, with the goal of developing preferred therapies for RAS-driven cancers.